Zusammenfassung
Chronische Hepatitis C-Infektionen stellen eine große Herausforderung für das Gesundheitssystem dar. Weltweit sind geschätzte 170 Millionen Menschen mit dem Virus infiziert. Hepatitis C-Patienten weisen eine hohe psychiatrische Komorbidität auf. Besonders häufig werden bei dieser Patientengruppe depressive Erkrankungen diagnostiziert. Interferon – alpha (IFN-alpha) wird heute zur Behandlung vieler viraler Erkrankungen eingesetzt und ist ein wichtiges Medikament bei der Behandlung der chronischen Hepatitis C. Die Entwicklung einer Depression ist jedoch leider eine häufige Begleiterscheinung einer solchen Therapie. Depressive Symptome beeinflussen den Krankheitsverlauf negativ, reduzieren die Compliance und die Lebensqualität der Betroffenen.
Summary
Chronic infection with the hepatitis C virus (HCV) is a major public-health-care problem worldwide, with approximately 170 million individuals affected. Hepatitis C is associated with an increased prevalence of psychiatric disorder, particularly depression. Interferon-alpha (IFN-alpha) is widely used in the treatment of viral infections, including hepatitis C. Unfortunately depression is a common side effect of IFN therapy. The presence of depressive symptoms is important because they have an adverse effect on the course of the illness and reduce the quality of life and the treatment compliance.
LITERATUR
Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M (2002) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72: 237–241
Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M (2002) Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 22: 86–90
Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003) Association of exaggerated hpa axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342–1345
Cassidy EM, Manning D, Byrne S, Bolger E, Murray F, Sharifi N, Wallace E, Keogan M, O'Keane V (2002) Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 16 (3): 230–234
Crone C, Gabriel GM (2003) Comprehensive review of hepatitis c for psychiatrists: Risk, screening, diagnosis, treatment, and interferon-based Therapy Complications. J Psychiatr Pract 9: 93–110
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL et al. (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321: 1501–1506
Dieperink E, Willenbring M, Ho S (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon-alpha: A review. Am J Psychiatry 157: 867–876
Donald CA, Ware JE (1982) The quantification of social contacts and resources. The Rand corporation, Santa Monica, Ca
Fahrenberg J, Myrtek M, Wilk D, Kreutel K (1986) Multimodale Erfassung der Lebenszufriedenheit: Eine Untersuchung an Herzkreislauf Patienten. Med Psychol 36: 347–354
Fontana RJ, Moyer CA, Sonnad S et al (2001) Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 96: 170–180
Golden J, O'Dwyer AM, Conroy RM (2005) Depression and anxiety in patients with hepatitis C: Prevalence, detection rates and risk factors. Gen Hosp Psychiatry 27: 431–438
Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL, Strathdee SA; STRIVE Project (2004) Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health. 81: 278–290
Hautzinger M, Bailer M, Worall H, Keller F (1992) Das Beck Depressionsinventar – BDI. Huber, Bern
Hilsabeck RC, Hassanein TI, Tarek, Carlson MD, Ziegler E, Perry W (2003) Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. (2003) J Inter Neuropsychol Soc 9: 847–854
Horikawa N, Yamazaki T, Izumi N, Uchihara M (2003) Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy. A prospective study. Gen Hosp Psychiatry 25: 34–38
Hnatyszyn HJ (2005) Chronic hepatitis C and genotyping: The clinical significance of determing HCV genotypes. Antivir Ther 10: 1–11
Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM (1997) Effects of interferon-alpha treatment of chronic hepatitis C patients on health-related quality of life. Dig Dis Sci 42: 2482–2486
Johnson ME, Fisher DG, Fenaughty A, Theno SA (1998) Hepatitis C virus and depression in drug users. Am J Gastroenterol 93: 785–789
Kirchberger J (1991) Lebensqualität von Brustkrebspatientinnen im Verlauf der stationären Rehabilitation. Diplomarbeit. Ludwig-Maximilian Universität, München
Kraus MR, Schäfer A, Al-Taie O, Scheurlen M (2005) Prophyactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon induced depression. J Vir Hepat 12: 96–100
Lee DH, Jamal H, Regenstein FG, Perillo RP (1997) Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 42: 186–191
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485–1492
Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, Rampello L (2001) Neuropsychiatric Effects and Type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 21: 273–278
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389
Nesic Z, Delic D, Prostran M, Stojanovic R, Vuckovic S, Todorovic Z (2004) Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis. Med Pregl 57(5–6): 219–226
Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K (1997) Depression during interferon therapy in chronic hepatitis C patients-a prospective study. Seishin Shinkeigaku Zasshi 99(3): 101–127
Poutiainen E, Hokkanen L, Niemi M et al (1994) Reversible cognitive decline during high dose alpha-interferon treatment. Pharmacol Biochem Behavior 47: 901–905
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH (2005) Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 66(1): 41–48
Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P, Roffi L (2005) Interferon-induced depression: Prevalence and management. Dig Liver Dis 37(2): 102–107
Schäfer M (2002) Neuro-psychiatrische Nebenwirkungen von Interferon-alpha bei Drogenabhängigen: Ursachen, Häufigkeit und Therapie. Suchttherapie (Suppl) 3: 572–577
Schäfer M, Schwaiger M (2003) Interferon-α assoziierte psychische Nebenwirkungen. Fortschr Neurol Psychiat 71: 469–476
Schäfer M (2005) Therapie der chronischen Hepatitis C bei Patienten mit psychischen Erkrankungen. Suchttherapie 6: 66–69
Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29(4): 637–638
Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I (2003) Depression severity and drug injection HIV risk behaviours. Am J Psychiatry 160: 1659–1662
Stewart A, Hays R, Ware J (1988) The MOS short form general health survey: Reliability and validity in a patient population. Med Care 26: 724–732
Sweeten TL, Ferris M, Mc Dougle CJ, Kwo P, Taylor MW (2001) Induction of indoleamine 2,3 dioxygenase in vivo by IFN-con 1. J Interferon Cytokine Res 21: 631–633
Turner EH, Blackwell AD (2005) 5-Hydroxytryptophan plus SSRI for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. Medical Hypotheses 65: 138–144
Varghese FP, Sherwood Brown E (2001) The hypothalamic-pituitary-adrenal axis in major depressive disorder: A brief primer for primary care physicians. Primary care companion. J Clin Psychiatry 3: 151–155
Wichers M, Maes M (2002) The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5(4): 375–388
Wichers MC, Koeck GH, Robaeys G, Verkerk R, Scharpe S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10: 538–544
Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, Miller AH (2005) Promoter polymorphisms of the Interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: Preliminary findings. Neuropsychobiology 52(2): 55–61
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baranyi, A., Rothenhäusler, HB. Interferon – alpha-induzierte Depressionen bei Patienten mit chronischen Hepatitis C-Infektionen. Psychiatrie 1, 51–56 (2005). https://doi.org/10.1007/s11326-005-0010-x
Issue Date:
DOI: https://doi.org/10.1007/s11326-005-0010-x